SI
SI
discoversearch

Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
2018 95 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Regeneron (REGN) is a biotech working in recombinant DNA technology. Until '94 it generally traded between 10 and 20 dollars until the FDA beat it up on it's treatment for Lou Gehrig's Disease. While it was trading at the $4 level at the end of '94, the former chairman of Merck(I believe) took the helm and the stock climbed back to about 11, then traded between 11 and 14. In late May, Option volume increased, news about a discovery concerning muscles was announced, and the stock has risen sharply to Friday, May 24 '96 close of 18.875.

Historically, the stock has failed around 22. Yet AMGEN has more than a 17.7% stake with warrants to increase it's stake to 20%, at 16$ per share. Could this be the time it breaks out?
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2018Asclepius was was a hero and god of medicine in ancient Greek religion and mythoBiotech Jim-yesterday
2017That is Sanofi job. Regeneron should go after lawyers if the want to break from Miljenko Zuanic-yesterday
2016They should go after some lawyers...Felix B-yesterday
2015Should Regeneron go after Asclepix? asclepix.comMiljenko Zuanic-Thursday
2014 Tyrosine kinase blocking collagen IV–derived peptide suppresses ocular neovascuBiotech Jim-Thursday
2013No, 45 days from Jan. 5.Miljenko Zuanic-Wednesday
2012Nice find. Was it stated somewhere when a final decision/appeal will be decidedFelix B-Wednesday
2011Very nice (plain language) review of the injunction case, ipwatchdog.comMiljenko Zuanic-Tuesday
2010They can extend for 3 more years on two specified targets with R&D call for Miljenko Zuanic-last Saturday
2009Really curious how SNY plays this after 2017 since their Ab collaboration ends. Felix B-last Saturday
2008They are still far from 30%! It looks as general positive that they are increasiMiljenko Zuanic-January 13
2007Is Sanofi obligated to keep/maintain %-tage ownership constant? Not obliged to dDewDiligence_on_SI-January 13
2006I do not know. Math may not add up completely. Sanofi bought ~80K shares, Yan anMiljenko Zuanic-January 13
2005Aren't those purchases simply to maintain SNY's pro rata equity stake asDewDiligence_on_SI-January 13
2004secfilings.nasdaq.com Sanofi is bit active.Miljenko Zuanic-January 13
2003I am not sure they are going after Soliris and PNH (regardless what was on slideMiljenko Zuanic-January 9
2002Look out Soliris. Competition for the paroxysmal nocturnal hemoglobinuria. AndBiotech Jim-January 9
2001FDA accepted SANOFI response to 483 (plan and implication of corrective actions)Miljenko Zuanic-January 9
2000Eylea 4Q sale flat over 3Q ($858M v 854). Holidays factor/effects??? Will see wMiljenko Zuanic-January 9
1999<It boggles my mind that the concept of an Ab to a particular epitope (even iMiljenko Zuanic-January 6
1998It boggles my mind that the concept of an Ab to a particular epitope (even if thFelix B-January 6
1997REGN versus AMGN, bloomberg.com There are two path here: A) make a deal with AMiljenko Zuanic-January 5
1996<Regeneron also has spent more than a year considering whether to build a secMiljenko Zuanic-January 5
1995This note: "One limitation of the study is that it didn’t nail down any newMiljenko Zuanic-12/22/2016
1994My view is: A LOT! I can not put specific numbers, for instance as part of theiMiljenko Zuanic-12/22/2016
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2017 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.